Welcome to our dedicated page for Proqr Therapeuti SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
Van Herk Investments B.V. and affiliated entities report beneficial ownership of 15,384,250 ProQR Therapeutics ordinary shares, representing 14.6% of the class based on 105,362,551 shares outstanding as of March 31, 2026.
The group amended its Schedule 13D to disclose that it will vote against agenda items 7, 8 and 9 at ProQR’s 2026 Annual General Meeting, which concern increasing authorized share capital, broad authority for the board to issue shares and authorization for share repurchases. Van Herk argues these proposals grant overly broad discretion over the capital structure, could cause substantial dilution without further shareholder approval, lack specific transaction justification and lack meaningful safeguards. They have engaged advisors to communicate with other shareholders and are evaluating potential legal proceedings while continuing to hold the shares for investment.
ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of options to buy 14,495 ordinary shares. These share options have an exercise price of $1.42 per share and expire on June 1, 2036, functioning as equity-based compensation rather than an open-market trade.
According to the vesting terms, 25% of the options vest and become exercisable on June 2, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments thereafter, contingent on continuous service. After this grant, the filing shows 14,495 derivative securities held.
ProQR Therapeutics N.V. director Hinsch Gylvin Lykke filed an initial Form 3 as an insider of the company. The data provided shows no reported transactions, no derivative positions, and no holding entries, so this filing mainly establishes insider status without disclosing any ownership changes.
ProQR Therapeutics N.V. reports the results of its 2026 annual general meeting held on June 2, 2026. Shareholders adopted the 2025 annual accounts and appropriation of net result with 99.7% of votes cast in favor.
They granted discharge from liability to Board members for their 2025 duties with 69.5% support and approved the appointment of Dr. Lykke Hinsch Gylvin as a non-executive Board member with 99.7% support. KPMG Accountants N.V. was appointed external auditor for the 2027 financial year with 99.8% approval.
Shareholders also approved amendments to the Articles of Association to increase authorized capital with 65.4% support, authorized the Board to issue ordinary shares with 64.3% support, and to repurchase ordinary shares with 66.7% support. Following the meeting, the Board confirmed updated Audit, Compensation/Nominating/Corporate Governance, and Research and Development committee compositions.
ProQR Therapeutics reported first quarter 2026 results showing continued investment in its RNA editing pipeline and a larger loss. Revenue was €2.0 million, down from €4.5 million a year earlier, mainly from its collaboration with Eli Lilly. The company recorded a net loss of €13.4 million, or €0.13 per share, versus €10.1 million, or €0.10 per share, in 2025, driven by R&D of €11.8 million and G&A of €3.9 million.
Cash and cash equivalents were €81.1 million at March 31, 2026, compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million. Management states this cash provides funding into at least the twelve months following issuance and, in forward-looking commentary, indicates a runway into mid 2027. Operationally, ProQR is advancing its Axiomer RNA editing platform, with lead program AX‑0810 on track for target engagement data in healthy volunteers in the second quarter of 2026 and an investigator-initiated biliary atresia trial in China planned ahead of Phase 2 development.
ProQR Therapeutics reported first quarter 2026 results and provided a pipeline update centered on its Axiomer RNA editing platform. Revenue was €2.0 million, down from €4.5 million a year earlier, and the company recorded a net loss of €13.4 million, or €0.13 per diluted share, versus a €10.1 million loss, or €0.10 per share, in 2025.
Cash and cash equivalents were €81.1 million at March 31, 2026 compared with €92.4 million at year-end 2025, with net cash used in operating activities of €11.1 million, improving from €15.8 million in the prior-year quarter. Lead program AX-0810 remains on track for target engagement data in the second quarter of 2026, and an investigator-initiated biliary atresia trial in China is planned with initial data targeted for the first half of 2027.
ProQR Therapeutics N.V. has called its 2026 Annual General Meeting for June 2, 2026 at 15:00 CEST in Amsterdam. Shareholders of record on May 5, 2026 may attend and vote.
The agenda includes adopting the 2025 annual accounts, releasing board members from liability for 2025, appointing Dr. Lykke Hinsch Gylvin as a new non-executive director for a four-year term, and appointing KPMG Accountants N.V. as external auditor for 2027.
Shareholders are also asked to approve an amendment of the articles to increase the authorized capital so each of the ordinary and preferred share classes has an authorized share capital of 270,000,000 shares, renew a five-year authorization for the board to issue ordinary shares up to 100% of authorized capital (with equity plans capped at 15% of issued capital), and authorize the board for 18 months to repurchase up to 10% of issued shares, plus an additional 10% in case of a material capital reorganization, at prices between US$0.01 and up to 110% of the average Nasdaq market price.
ProQR Therapeutics, a clinical-stage company focused on RNA therapies using its Axiomer™ RNA editing platform, has nominated Dr. Lykke Hinsch Gylvin to its Board of Directors. She is Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim and has over 20 years of global pharmaceutical leadership experience.
The nomination will be submitted for shareholder approval at ProQR’s upcoming Annual General Meeting. If approved, Dr. Hinsch Gylvin will serve as an independent non-executive director, bringing broad drug development, regulatory, and medical affairs experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck.
ProQR Therapeutics used a virtual analyst and investor event to showcase progress on its Axiomer RNA editing pipeline and outline upcoming clinical milestones. The lead program, AX-0810 targeting NTCP, is expected to deliver target engagement data from healthy volunteers in the first half of 2026, with biliary atresia chosen as the initial Phase 2 indication based on biological rationale and unmet need. The company also announced two new programs, AX-0811 and AX-0422, and highlighted additional candidates such as AX-2911 and AX-2402 as part of a growing portfolio. ProQR emphasized AI-enabled discovery, high-throughput screening, and its partnership with Ginkgo Bioworks to design and optimize RNA editing therapeutics. Management stated that multiple clinical data readouts are expected across the pipeline within its current cash runway, which extends into mid-2027.
ProQR Therapeutics used a virtual analyst and investor event to showcase progress on its Axiomer RNA editing pipeline and outline upcoming clinical milestones. The lead program, AX-0810 targeting NTCP, is expected to deliver target engagement data from healthy volunteers in the first half of 2026, with biliary atresia chosen as the initial Phase 2 indication based on biological rationale and unmet need. The company also announced two new programs, AX-0811 and AX-0422, and highlighted additional candidates such as AX-2911 and AX-2402 as part of a growing portfolio. ProQR emphasized AI-enabled discovery, high-throughput screening, and its partnership with Ginkgo Bioworks to design and optimize RNA editing therapeutics. Management stated that multiple clinical data readouts are expected across the pipeline within its current cash runway, which extends into mid-2027.
ProQR Therapeutics announced an AI-focused strategy for its Axiomer™ RNA editing platform, highlighted by a new partnership with Ginkgo Bioworks and the creation of an AI Advisory Board. Ginkgo is providing access to its 50+ instrument autonomous lab, Nebula, and has made a strategic equity investment in ProQR.
ProQR plans to move its first AI-enabled RNA editing programs into the clinic, with a clinical trial application targeted for mid-2026 and initial clinical data anticipated by year-end 2026. The company is also hosting a virtual Investor and Analyst event to present broader pipeline updates, new programs with upcoming clinical readouts, and the primary indication for AX-0810.
ProQR Therapeutics announced an AI-focused strategy for its Axiomer™ RNA editing platform, highlighted by a new partnership with Ginkgo Bioworks and the creation of an AI Advisory Board. Ginkgo is providing access to its 50+ instrument autonomous lab, Nebula, and has made a strategic equity investment in ProQR.
ProQR plans to move its first AI-enabled RNA editing programs into the clinic, with a clinical trial application targeted for mid-2026 and initial clinical data anticipated by year-end 2026. The company is also hosting a virtual Investor and Analyst event to present broader pipeline updates, new programs with upcoming clinical readouts, and the primary indication for AX-0810.